Olenphogy Introduces TriPhasic Delivery Architecture to Address the Nutrient Bioavailability Gap

FAIRFAX, VA — April, 2026 — OLENPHOGY Wellness Inc. today announced its official U.S. market entry with a technical resolution to the "Bioavailability Gap" in metabolic supplementation: the TriPhasic Berberine system. While standard berberine HCl is often rejected by the gut's P-glycoprotein (P-gp) efflux system, OLENPHOGY utilizes a multi-stage delivery architecture to maintain consistent plasma levels for up to 12 hours.

The Core Innovation: Overcoming the "Absorption Barrier" with DHB 98% 

The primary challenge in berberine efficacy is its low intestinal absorption rate, typically below 1%. OLENPHOGY resolves this through 98% pure Dihydroberberine (DHB), a hydrogenated derivative that bypasses standard conversion roadblocks:

• 5X Absorption Leadership: Based on comparative pharmacokinetic profiles, DHB 98% achieves 5 times the bioavailability (AUC) of standard berberine HCl.
• Direct-to-Plasma Pathway: Unlike standard extracts, DHB is not a substrate for P-gp efflux, allowing it to pass through the intestinal wall and convert to active berberine directly in the plasma.
• High-Efficiency Utilization: Due to this 500% efficiency increase, one capsule provides cellular utilization equivalent to several standard high-dose capsules without the typical gastrointestinal burden.

The TriPhasic Delivery Architecture: 12-Hour Sustainability 

To move beyond the "peak and crash" cycle of traditional supplements, OLENPHOGY engineers a three-stage release profile based on 2024 pharmacokinetic analysis:

• Phase 1: Rapid Activation (98% DHB): Bypasses the P-gp barrier for immediate peak plasma concentration.
• Phase 2: Extended Sustainability (Liposomal): Employs phospholipid bilayer encapsulation to protect ingredients and ensure a controlled, time-released flow.
• Phase 3: Foundational Support (97% Berberine HCl): Provides a high-purity clinical base to maintain long-term metabolic and gut microbiome balance.

Expert Insight on Metabolic Precision 

“We didn’t design this formula to win a dosage race on a label; we designed it to win the ‘cellular race’ inside the body,” says the OLENPHOGY Scientific Advisory Board. “By focusing on DHB’s 5X absorption, we are providing a choice for biohackers, athletes, and professionals focused on metabolic optimization.”

Synergistic Co-Factors for Systemic Support 

The formula incorporates clinical synergists to ensure efficacy is met with maximum comfort:

• Metabolic Defense: Active Benfotiamine is included to defend cells against metabolic byproducts (AGEs) and support healthy glucose pathways.
• Digestive Comfort: Standardized Ginger Root Extract (5% Gingerols) ensures a superior experience, mitigating the sensitivities common in high-potency berberine.

Availability and Purchasing 

TriPhasic Berberine is now available through Olenphogy.com and Amazon.com, marking the start of the brand's retail expansion in the United States.

About OLENPHOGY 

OLENPHOGY is a science-first wellness company dedicated to bridging the gap between clinical nutrient potential and real-world biological results. Headquartered in Fairfax, Virginia, the company focuses on "Smarter Formulations" that prioritize bioavailability, synergistic integrity, and rigorous independent testing. By combining cutting-edge delivery systems with high-purity ingredients, OLENPHOGY provides elite-level support for the modern consumer.

Media Contact: 

Contact Name: Hebe Lee 
Title: PR Manager 
Company: OLENPHOGY 
Address: 3060 Williams Dr #558, Fairfax, VA 22031 
Phone: 1-888-588-OLEN (6536)
Email: hello@olenphogy.com 
Website: https://www.olenphogy.com

References

1.Xu X, Yi H, Wu J, et al. Therapeutic effect of berberine on metabolic diseases: both pharmacological data and clinical evidence. Biomed Pharmacother. 2021;133:110984. doi:10.1016/j.biopha.2020.110984.

2.Wang H, Zhang H, Gao Z, Zhang Q, Gu C. The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Front Cell Infect Microbiol. 2022;12:854885. doi:10.3389/fcimb.2022.854885.

3.Feng W, Wang WN, Chen PY, Du BY, Li HL. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. 2019;9(7):1923-1951. doi:10.7150/thno.30787.

4.Moon JM, Ratliff KM, Hagele AM, et al. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients. 2021;14(1):124. doi:10.3390/nu14010124.

5.Bozic I, Lavrnja I. Thiamine and benfotiamine: Focus on their therapeutic potential. Heliyon. 2023;9(11):e21839. doi:10.1016/j.heliyon.2023.e21839.

6.Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res. 2010;61(6):482-488. doi:10.1016/j.phrs.2010.02.008.

7.Sharma S, Shukla MK, Sharma KC, et al. Revisiting the therapeutic potential of gingerols against different pharmacological activities. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(4):633-647. doi:10.1007/s00210-022-02372-7.

8.Wang J, Ke W, Bao R, Hu X, Chen F. Ginger and its constituents: role in treatment of metabolic syndrome. Nutrients. 2020;12(4):1141. doi:10.3390/nu12041141.